The U.S. Food and Drug Administration (USFDA) has suspended the biologics license of Ixchiq (Chikungunya Vaccine, Live), ...

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

Robert Kennedy Jr. signs recommendation eliminating mercury-based thimerosal from influenza vaccines, fulfilling anti-vaccine advocacy despite FDA safety data.

The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

Hey, good morning. Today, we see CBER suspend the license for a chikungunya vaccine, look at a push to recall a safety and ...

Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly ...

The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a ...